| Year |
Citation |
Score |
| 2024 |
Kopp KO, Li Y, Glotfelty EJ, Tweedie D, Greig NH. Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration. Biomolecules. 14. PMID 39062586 DOI: 10.3390/biom14070872 |
0.718 |
|
| 2024 |
Liu D, Hsueh SC, Tweedie D, Price N, Glotfelty E, Lecca D, Telljohann R, deCabo R, Hoffer BJ, Greig NH. Chronic inflammation with microglia senescence at basal forebrain: impact on cholinergic deficit in Alzheimer's brain haemodynamics. Brain Communications. 6: fcae204. PMID 38978722 DOI: 10.1093/braincomms/fcae204 |
0.709 |
|
| 2024 |
Chen YH, Kuo TT, Wang V, Cheng PW, Huang EY, Ma KH, Greig NH, Olson L, Hoffer BJ, Tseng KY. Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. Journal of Parkinson's Disease. PMID 38905058 DOI: 10.3233/JPD-240080 |
0.364 |
|
| 2024 |
Bader M, Li Y, Lecca D, Rubovitch V, Tweedie D, Glotfelty E, Rachmany L, Kim HK, Choi HI, Hoffer BJ, Pick CG, Greig NH, Kim DS. Corrigendum to "Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury" [Neurobiology of Disease Volume 124 (2019) 439-453 /YNBDI_4338]. Neurobiology of Disease. 106563. PMID 38890024 DOI: 10.1016/j.nbd.2024.106563 |
0.723 |
|
| 2024 |
Kopp KO, Glotfelty EJ, Li Y, Lahiri DK, Greig NH. Type 2 diabetes mellitus/obesity drugs: a neurodegenerative disorders savior or a bridge too far? Ageing Research Reviews. 102343. PMID 38762101 DOI: 10.1016/j.arr.2024.102343 |
0.712 |
|
| 2024 |
Wang V, Tseng KY, Kuo TT, Huang EY, Lan KL, Chen ZR, Ma KH, Greig NH, Jung J, Choi HI, Olson L, Hoffer BJ, Chen YH. Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice. Journal of Biomedical Science. 31: 38. PMID 38627765 DOI: 10.1186/s12929-024-01025-6 |
0.433 |
|
| 2024 |
Yu SJ, Wang Y, Shen H, Bae EK, Li Y, Sambamurti K, Tones MA, Zaleska MM, Hoffer BJ, Greig NH. DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease. Geroscience. PMID 38563864 DOI: 10.1007/s11357-024-01116-0 |
0.313 |
|
| 2023 |
Glotfelty EJ, Tovar-Y-Romo LB, Hsueh SC, Tweedie D, Li Y, Harvey BK, Hoffer BJ, Karlsson TE, Olson L, Greig NH. The RhoA-ROCK1/ROCK2 Pathway Exacerbates Inflammatory Signaling in Immortalized and Primary Microglia. Cells. 12. PMID 37408199 DOI: 10.3390/cells12101367 |
0.716 |
|
| 2023 |
Glotfelty EJ, Hsueh SC, Claybourne Q, Bedolla A, Kopp KO, Wallace T, Zheng B, Luo Y, Karlsson TE, McDevitt RA, Olson L, Greig NH. Microglial Nogo delays recovery following traumatic brain injury in mice. Glia. PMID 37401784 DOI: 10.1002/glia.24436 |
0.731 |
|
| 2023 |
Kopp KO, Greer ME, Glotfelty EJ, Hsueh SC, Tweedie D, Kim DS, Reale M, Vargesson N, Greig NH. A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders. Biomolecules. 13. PMID 37238617 DOI: 10.3390/biom13050747 |
0.715 |
|
| 2023 |
Kuo TT, Chen YH, Wang V, Huang EY, Ma KH, Greig NH, Jung J, Choi HI, Olson L, Hoffer BJ, Tseng KY. PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease. International Journal of Molecular Sciences. 24. PMID 36902115 DOI: 10.3390/ijms24054687 |
0.423 |
|
| 2022 |
Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment. Pharmacological Research. 106550. PMID 36372278 DOI: 10.1016/j.phrs.2022.106550 |
0.738 |
|
| 2022 |
Hsueh SC, Scerba MT, Tweedie D, Lecca D, Kim DS, Baig AM, Kim YK, Hwang I, Kim S, Selman WR, Hoffer BJ, Greig NH. Activity of a Novel Anti-Inflammatory Agent F-3,6'-dithiopomalidomide as a Treatment for Traumatic Brain Injury. Biomedicines. 10. PMID 36289711 DOI: 10.3390/biomedicines10102449 |
0.315 |
|
| 2022 |
Lecca D, Jung YJ, Scerba MT, Hwang I, Kim YK, Kim S, Modrow S, Tweedie D, Hsueh SC, Liu D, Luo W, Glotfelty E, Li Y, Wang JY, Luo Y, ... ... Greig NH, et al. Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35234334 DOI: 10.1002/alz.12610 |
0.683 |
|
| 2021 |
Li Y, Glotfelty EJ, Karlsson T, Fortuno LV, Harvey BK, Greig NH. The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration. Journal of Neurochemistry. PMID 34569615 DOI: 10.1111/jnc.15521 |
0.72 |
|
| 2021 |
Hsueh SC, Luo W, Tweedie D, Kim DS, Kim YK, Hwang I, Gil JE, Han BS, Chiang YH, Selman W, Hoffer BJ, Greig NH. -Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge. Acs Pharmacology & Translational Science. 4: 980-1000. PMID 33860215 DOI: 10.1021/acsptsci.1c00042 |
0.315 |
|
| 2021 |
Wang V, Kuo TT, Huang EY, Ma KH, Chou YC, Fu ZY, Lai LW, Jung J, Choi HI, Choi DS, Li Y, Olson L, Greig NH, Hoffer BJ, Chen YH. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. Acs Pharmacology & Translational Science. 4: 858-869. PMID 33860208 DOI: 10.1021/acsptsci.1c00013 |
0.461 |
|
| 2020 |
Yu SJ, Chen S, Yang YY, Glotfelty EJ, Jung J, Kim HK, Choi HI, Choi DS, Hoffer BJ, Greig NH, Wang Y. PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease. Frontiers in Neuroscience. 14: 785. PMID 32848559 DOI: 10.3389/Fnins.2020.00785 |
0.706 |
|
| 2020 |
Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease. Expert Opinion On Investigational Drugs. 1-8. PMID 32412796 DOI: 10.1080/13543784.2020.1764534 |
0.73 |
|
| 2019 |
Bader M, Li Y, Tweedie D, Shlobin NA, Bernstein A, Rubovitch V, Tovar-Y-Romo LB, DiMarchi RD, Hoffer BJ, Greig NH, Pick CG. Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury. Frontiers in Cell and Developmental Biology. 7: 356. PMID 31998717 DOI: 10.3389/Fcell.2019.00356 |
0.374 |
|
| 2019 |
Jung YJ, Tweedie D, Scerba MT, Greig NH. Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. Frontiers in Cell and Developmental Biology. 7: 313. PMID 31867326 DOI: 10.3389/fcell.2019.00313 |
0.303 |
|
| 2019 |
Greig NH, Lecca D, Hsueh SC, Nogueras-Ortiz C, Kapogiannis D, Tweedie D, Glotfelty EJ, Becker RE, Chiang YH, Hoffer BJ. (-)-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury. Cns Neuroscience & Therapeutics. PMID 31828969 DOI: 10.1111/Cns.13274 |
0.705 |
|
| 2019 |
Li Y, Glotfelty EJ, Namdar I, Tweedie D, Olson L, Hoffer BJ, DiMarchi RD, Pick CG, Greig NH. Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. Experimental Neurology. 113113. PMID 31730763 DOI: 10.1016/J.Expneurol.2019.113113 |
0.749 |
|
| 2019 |
Glotfelty EJ, Delgado T, Tovar-Y-Romo LB, Luo Y, Hoffer B, Olson L, Karlsson T, Mattson MP, Harvey B, Tweedie D, Li Y, Greig NH. Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. Acs Pharmacology & Translational Science. 2: 66-91. PMID 31396586 DOI: 10.1021/acsptsci.9b00003 |
0.752 |
|
| 2018 |
Bader M, Li Y, Lecca D, Rubovitch V, Tweedie D, Glotfelty E, Rachmany L, Kim HK, Choi HI, Hoffer BJ, Pick CG, Greig NH, Kim DS. Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury. Neurobiology of Disease. PMID 30471415 DOI: 10.1016/J.Nbd.2018.11.023 |
0.745 |
|
| 2018 |
Chen S, Yu SJ, Li Y, Lecca D, Glotfelty E, Kim HK, Choi HI, Hoffer BJ, Greig NH, Kim DS, Wang Y. Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. Scientific Reports. 8: 13953. PMID 30209317 DOI: 10.1038/s41598-018-31455-w |
0.699 |
|
| 2018 |
Chen S, Yu SJ, Li Y, Lecca D, Glotfelty E, Kim HK, Choi HI, Hoffer BJ, Greig NH, Kim DS, Wang Y. Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease. Scientific Reports. 8: 10722. PMID 30013201 DOI: 10.1038/S41598-018-28449-Z |
0.715 |
|
| 2017 |
Becker RE, Kapogiannis D, Greig NH. Does traumatic brain injury hold the key to the Alzheimer's puzzle? Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29245000 DOI: 10.1016/j.jalz.2017.11.007 |
0.307 |
|
| 2017 |
Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH. A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. Cell Transplantation. 26: 1560-1571. PMID 29113464 DOI: 10.1177/0963689717721234 |
0.353 |
|
| 2017 |
Hoffer BJ, Pick CG, Hoffer ME, Becker RE, Chiang YH, Greig NH. Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine. Journal of Biomedical Science. 24: 71. PMID 28886718 DOI: 10.1186/s12929-017-0377-1 |
0.303 |
|
| 2017 |
Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH. A New Treatment Strategy for Parkinson's Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway. Cell Transplantation. PMID 28447569 DOI: 10.3727/096368917X695669 |
0.354 |
|
| 2017 |
Brix KA, Brody DL, Grimes JB, Yitzhak A, Agoston D, Aldag M, Armstrong R, Arun P, Audette M, Babcock D, Balaban C, Banton R, Bellgowan P, Borkholder D, Broglio S, ... ... Greig N, et al. Military Blast Exposure and Chronic Neurodegeneration: Summary of Working Groups and Expert Panel Findings and Recommendations Journal of Neurotrauma. 34. DOI: 10.1089/Neu.2017.5222 |
0.315 |
|
| 2016 |
Tamargo IA, Bader M, Li Y, Yu SJ, Wang Y, Talbot K, DiMarchi RD, Pick CG, Greig NH. Novel GLP-1R/GIPR co-agonist "twincretin" is neuroprotective in cell and rodent models of mild traumatic brain injury. Experimental Neurology. PMID 27845037 DOI: 10.1016/j.expneurol.2016.11.005 |
0.317 |
|
| 2016 |
Chiu CC, Liao YE, Yang LY, Wang JY, Tweedie D, Karnati HK, Greig NH, Wang JY. Neuroinflammation in animal models of traumatic brain injury. Journal of Neuroscience Methods. PMID 27382003 DOI: 10.1016/j.jneumeth.2016.06.018 |
0.304 |
|
| 2016 |
Tweedie D, Fukui K, Li Y, Yu QS, Barak S, Tamargo IA, Rubovitch V, Holloway HW, Lehrmann E, Wood WH, Zhang Y, Becker KG, Perez E, Van Praag H, Luo Y, ... ... Greig NH, et al. Cognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic Mechanisms. Plos One. 11: e0156493. PMID 27254111 DOI: 10.1371/Journal.Pone.0156493 |
0.318 |
|
| 2015 |
Li Y, Bader M, Tamargo I, Rubovitch V, Tweedie D, Pick CG, Greig NH. Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. Journal of Neurochemistry. 135: 1203-17. PMID 25982185 DOI: 10.1111/jnc.13169 |
0.33 |
|
| 2014 |
Greig NH, Tweedie D, Rachmany L, Li Y, Rubovitch V, Schreiber S, Chiang YH, Hoffer BJ, Miller J, Lahiri DK, Sambamurti K, Becker RE, Pick CG. Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S62-75. PMID 24529527 DOI: 10.1016/J.Jalz.2013.12.011 |
0.3 |
|
| 2013 |
Eakin K, Li Y, Chiang YH, Hoffer BJ, Rosenheim H, Greig NH, Miller JP. Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. Plos One. 8: e82016. PMID 24312624 DOI: 10.1371/journal.pone.0082016 |
0.328 |
|
| 2013 |
Tweedie D, Rachmany L, Rubovitch V, Lehrmann E, Zhang Y, Becker KG, Perez E, Miller J, Hoffer BJ, Greig NH, Pick CG. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Experimental Neurology. 239: 170-82. PMID 23059457 DOI: 10.1016/J.Expneurol.2012.10.001 |
0.302 |
|
| 2013 |
Rachmany L, Tweedie D, Li Y, Rubovitch V, Holloway HW, Miller J, Hoffer BJ, Greig NH, Pick CG. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordrecht, Netherlands). 35: 1621-36. PMID 22892942 DOI: 10.1007/s11357-012-9464-0 |
0.351 |
|
| 2012 |
Ray B, Bailey J, Nelson P, Greig N, Lahiri D. P1-215: Rivastigmine promotes APP processing via α-secretase pathway: Studies from neuron culture and animal model to postmortem brain tissues and its implications in Alzheimer's disease (AD) Alzheimer's & Dementia. 8: P182-P183. DOI: 10.1016/J.Jalz.2012.05.494 |
0.353 |
|
| 2009 |
Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes. 58: 318-28. PMID 18984744 DOI: 10.2337/Db08-0799 |
0.312 |
|
| 2004 |
Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK. New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. Annals of the New York Academy of Sciences. 1035: 290-315. PMID 15681814 DOI: 10.1196/Annals.1332.018 |
0.314 |
|
| 2004 |
Lahiri DK, Bailey J, Alley G, Chen D, Sambamurti K, Greig N. O3-06-01 Effects of diverse cholinesterase inhibitors and memantine on the amyloid pathway and its implications in Alzheimer's disease Neurobiology of Aging. 25: S63-S64. DOI: 10.1016/S0197-4580(04)80214-8 |
0.307 |
|
| 2002 |
Rogers JT, Randall JD, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, Cahill CM, Moir R, Lahiri DK, Greig N, Sarang SS, et al. Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. Journal of Molecular Neuroscience : Mn. 19: 77-82. PMID 12212798 DOI: 10.1007/S12031-002-0014-6 |
0.34 |
|
| 2000 |
Culmsee C, Zhu X, Greig N, Guo Z, Camandola S, Crump S, Zhao D, Mattson M. The P53 inhibitor pifithrin-α protects neurons in experimental models of Alzheimer's disease Neurobiology of Aging. 21: 44. DOI: 10.1016/S0197-4580(00)82874-2 |
0.332 |
|
| 1996 |
Ingram DK, Shimada A, Spangler EL, Ikari H, Hengemihle J, Kuo H, Greig N. Cognitive enhancement. New strategies for stimulating cholinergic, glutamatergic, and nitric oxide systems. Annals of the New York Academy of Sciences. 786: 348-361. PMID 8687034 DOI: 10.1111/J.1749-6632.1996.Tb39076.X |
0.337 |
|
| 1984 |
Greig N, Newell D, Hellmann K. Short communication: Metrazol enhances brain penetration and therapeutic efficacy of some anticancer agents: implications for brain metastases Clinical & Experimental Metastasis. 2: 55-59. PMID 6543690 DOI: 10.1007/Bf00132306 |
0.332 |
|
| 1983 |
Greig N, Hellmann K. Enhanced cerebrovascular permeability by Metrazol: significance for brain metastases. Clinical & Experimental Metastasis. 1: 83-95. PMID 6085721 DOI: 10.1007/Bf00118475 |
0.325 |
|
| Show low-probability matches. |